Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • 19-28z CAR T cells: Phase I data

    Juno Therapeutics Inc., Seattle, Wash. Product: 19-28z CAR T cells (JCAR015) Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the …

    Published on 12/15/2014
  • 19-28z CAR T cells: Phase I data

    Juno Therapeutics Inc., Seattle, Wash. Product: 19-28z CAR T cells (JCAR015) Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the …

    Published on 12/15/2014
  • Adcetris brentuximab vedotin: Additional Phase III data

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Adcetris brentuximab vedotin (SGN-35) Business: Cancer Molecular target: CD30 Description: Antibody-…

    Published on 12/15/2014
  • ATIR: Interim Phase II data

    Kiadis Pharma Beta.V., Amsterdam, the Netherlands Product: ATIR Business: Transplant Molecular target: Not applicable Description: Cell-based therapy containing mismatched donor lymphocytes depleted of allo-reactive T …

    Published on 12/15/2014
  • Blincyto blinatumomab: Phase II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Blincyto blinatumomab (AMG 103) (formerly MT103) Business: Cancer Molecular target: CD19 Description: Bispecific T…

    Published on 12/15/2014
  • Brexpiprazole: Phase III data

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Brexpiprazole (OPC-34712) Business: Neurology Molecular target: Dopamine D2 receptor; Serotonin (5-HT1A) receptor …

    Published on 12/15/2014
  • Brexpiprazole: Phase III data

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Brexpiprazole (OPC-34712) Business: Neurology Molecular target: Dopamine D2 receptor; Serotonin (5-HT1A) receptor …

    Published on 12/15/2014
  • Brexpiprazole: Phase III data

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Brexpiprazole (OPC-34712) Business: Neurology Molecular target: Dopamine D2 receptor; Serotonin (5-HT1A) receptor …

    Published on 12/15/2014
  • Brexpiprazole: Phase III data

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Brexpiprazole (OPC-34712) Business: Neurology Molecular target: Dopamine D2 receptor; Serotonin (5-HT1A) receptor …

    Published on 12/15/2014
  • CCX140: Additional Phase II data

    ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif. Product: CCX140 Business: Renal Molecular target: CC chemokine receptor 2 (CCR2) (CD192) Description: Inhibitor of CC chemokine receptor 2 (CCR2; CD192) Indication:…

    Published on 12/15/2014
  • CTL019: Phase II data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland University of Pennsylvania, Philadelphia, Pa. Product: CTL019 (formerly CART-19) Business: Cancer Molecular target: CD19 Description: Autologous T cells loaded with a…

    Published on 12/15/2014
  • CTL019: Updated Phase I/IIa data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland University of Pennsylvania, Philadelphia, Pa. Product: CTL019 (formerly CART-19) Business: Cancer Molecular target: CD19 Description: Autologous T cells loaded with a…

    Published on 12/15/2014
  • GLYX-13: Additional Phase IIb data

    Naurex Inc., Evanston, Ill. Product: GLYX-13 (formerly NT-13) Business: Neurology Molecular target: NMDA receptor Description: Glycine site functional partial agonist (GFPA) of the NMDA receptor Indication: Adjunctive …

    Published on 12/15/2014
  • JCAR014: Phase I data

    Juno Therapeutics Inc., Seattle, Wash. Product: JCAR014 Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing a chimeric antigen receptor (CAR) specific to the CD19 antigen Indication: Treat…

    Published on 12/15/2014
  • JCAR017: Phase I data

    Juno Therapeutics Inc., Seattle, Wash. Product: JCAR017 Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing a chimeric antigen receptor (CAR) specific to the CD19 antigen Indication: Treat…

    Published on 12/15/2014
  • JTCR016: Phase I/II data

    Juno Therapeutics Inc., Seattle, Wash. Product: JTCR016 Business: Cancer Molecular target: Wilms tumor 1 (WT1) Description: T cell receptor (TCR) targeting Wilms tumor 1 (WT1) Indication: Treat acute myelogenous …

    Published on 12/15/2014
  • Keytruda pembrolizumab: Additional Phase Ib data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Keytruda pembrolizumab (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PDCD1) (PD-1) (CD279) Description: …

    Published on 12/15/2014
  • Kyprolis carfilzomib: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: Kyprolis carfilzomib (PR-171, ONO-7057) Business: Cancer Molecular target: Proteasome Description: …

    Published on 12/15/2014
  • LentiGlobin BB305 gene therapy: Additional Phase I/II data

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Product: LentiGlobin BB305 gene therapy Business: Hematology Molecular target: NA Description: Autologous CD34+ stem cells transduced ex vivo with a lentiviral vector …

    Published on 12/15/2014
  • LentiGlobin BB305 gene therapy: Additional Phase I/II data

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Product: LentiGlobin BB305 gene therapy Business: Hematology Molecular target: NA Description: Autologous CD34+ stem cells transduced ex vivo with a lentiviral vector …

    Published on 12/15/2014
  • Lurbinectedin: Updated Phase II data

    PharmaMar S.A., Madrid, Spain Product: Lurbinectedin (PM01183, PM1183) Business: Cancer Molecular target: NA Description: DNA minor groove binder Indication: Treat platinum-resistant or refractory ovarian cancer …

    Published on 12/15/2014
  • Luspatercept: Additional Phase II data

    Acceleron Pharma Inc. (NASDAQ:XLRN), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: Luspatercept (ACE-536) Business: Hematology Molecular target: Activin receptor type 2B (ACVR2B) Description: …

    Published on 12/15/2014
  • Opdivo nivolumab: Phase Ib data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Opdivo nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell …

    Published on 12/15/2014
  • Pembrolizumab: Additional Phase Ib data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Pembrolizumab (Keytruda) (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PDCD1) (PD-1) (CD279) Description: …

    Published on 12/15/2014
  • RG6013: Phase I data

    Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: RG6013, ACE910 Business: Hematology Molecular target: …

    Published on 12/15/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993